11 results on '"Angeles, Arlou Kristina"'
Search Results
2. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
- Author
-
Janke, Florian, Angeles, Arlou Kristina, Riediger, Anja Lisa, Bauer, Simone, Reck, Martin, Stenzinger, Albrecht, Schneider, Marc A., Muley, Thomas, Thomas, Michael, Christopoulos, Petros, and Sültmann, Holger
- Published
- 2022
- Full Text
- View/download PDF
3. Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
- Author
-
Angeles, Arlou Kristina, Christopoulos, Petros, Yuan, Zhao, Bauer, Simone, Janke, Florian, Ogrodnik, Simon John, Reck, Martin, Schlesner, Matthias, Meister, Michael, Schneider, Marc A., Dietz, Steffen, Stenzinger, Albrecht, Thomas, Michael, and Sültmann, Holger
- Published
- 2021
- Full Text
- View/download PDF
4. Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer.
- Author
-
Eickelschulte, Samaneh, Riediger, Anja Lisa, Angeles, Arlou Kristina, Janke, Florian, Duensing, Stefan, Sültmann, Holger, and Görtz, Magdalena
- Subjects
EVALUATION of medical care ,MINIMALLY invasive procedures ,EARLY detection of cancer ,RISK assessment ,PROTEOMICS ,MOLECULAR biology ,PATIENT monitoring ,GENOMICS ,GENE expression profiling ,BODY fluid examination ,TUMOR markers ,DECISION making in clinical medicine ,PROSTATE tumors ,EPIGENOMICS - Abstract
Simple Summary: Prostate cancer is a heterogeneous disease and a major cause of cancer deaths worldwide. The most widely used prostate cancer biomarker, prostate-specific antigen, lacks sensitivity and specificity in the diagnosis of malignant disease. Hence, novel tissue-based biomarkers have emerged for the detection and risk assessment of prostate cancer. Over the past years, liquid biopsy biomarkers introduced a new diagnostic concept to complement current tissue diagnosis strategies. Liquid biopsies non-invasively provide a characterization of heterogenous tumor profiles. Here, we highlight the most prominent tissue and liquid biopsy biomarkers for the detection and risk assessment of prostate cancer. Current strategies for the clinical management of prostate cancer are inadequate for a precise risk stratification between indolent and aggressive tumors. Recently developed tissue-based molecular biomarkers have refined the risk assessment of the disease. The characterization of tissue biopsy components and subsequent identification of relevant tissue-based molecular alterations have the potential to improve the clinical decision making and patient outcomes. However, tissue biopsies are invasive and spatially restricted due to tumor heterogeneity. Therefore, there is an urgent need for complementary diagnostic and prognostic options. Liquid biopsy approaches are minimally invasive with potential utility for the early detection, risk stratification, and monitoring of tumors. In this review, we focus on tissue and liquid biopsy biomarkers for early diagnosis and risk stratification of prostate cancer, including modifications on the genomic, epigenomic, transcriptomic, and proteomic levels. High-risk molecular alterations combined with orthogonal clinical parameters can improve the identification of aggressive tumors and increase patient survival. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Phenotypic characterization of the novel, non-hotspot oncogenic KRAS mutants E31D and E63K.
- Author
-
Angeles, Arlou Kristina J., Yu, Ryan Timothy D., Cutiongco-De La Paz, Eva Maria, and Garcia, Reynaldo L.
- Subjects
- *
GENETIC mutation , *EPIDERMAL growth factor receptors , *SOMATIC mutation , *CELL transformation - Abstract
KRAS proto-oncogene, GTPase (KRAS) functions as a molecular switch at the apex of multiple signaling pathways controlling cell proliferation, differentiation, migration, and survival. Canonical KRAS mutants, such as those in codons 12 and 13, produce constitutively active oncoproteins that short-circuit epidermal growth factor receptor (EGFR)-initiated signaling, resulting in dysregulated downstream effectors associated with cellular transformation. Therefore, anti-EGFR therapy provides little to no clinical benefit to patients with activating KRAS mutations. Current genotyping procedures based on canonical mutation detection only account for ~40% of non-responders, highlighting the need to identify additional predictive biomarkers. In the present study, two novel non-hotspot KRAS mutations were functionally characterized in vitro: KRAS E31D was identified from a genetic screen of colorectal cancer specimens at the UP-National Institutes of Health. KRAS E63K is curated in the Catalogue of Somatic Mutations in Cancer database. Similar to the canonical mutants KRAS G12D and KRAS G13D, NIH3T3 cells overexpressing KRAS E31D and KRAS E63K showed altered morphology and were characteristically smaller, rounder, and highly refractile compared with their non-transformed counterparts. Filamentous actin staining also indicated cytoplasmic shrinkage, membrane ruffling, and formation of pseudopod protrusions. Further, they displayed higher proliferative rates and higher migratory rates in scratch wound assays compared with negative controls. These empirical findings suggest the activating impact of the novel KRAS mutations, which may contribute to resistance to anti-EGFR therapy. Complementary studies to elucidate the molecular mechanisms underlying the transforming effect of the rare mutants are required. In parallel, their oncogenic capacity in vivo should also be investigated. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer.
- Author
-
Angeles, Arlou Kristina, Janke, Florian, Bauer, Simone, Christopoulos, Petros, Riediger, Anja Lisa, and Sültmann, Holger
- Subjects
- *
GENETIC mutation , *SEQUENCE analysis , *DNA , *INDIVIDUALIZED medicine , *EXTRACELLULAR space , *TUMORS , *GENETIC techniques , *NUCLEIC acids , *EPIGENOMICS ,BODY fluid examination - Abstract
Simple Summary: Liquid biopsies provide a non-invasive means to diagnose and profile tumors when tissue is not available. Sequence-based analysis of cell-free DNA (cfDNA) is frequently used to characterize genomic alterations, with a focus on driver mutations or mechanisms of acquired therapy resistance. However, the epigenome of cfDNA also contains additional information about the tumor, which might open new possibilities for clinical applications. Recent highlighted publications are reviewed on the analysis of fragmentation, epigenomic alterations, as well as nucleosome modifications using cfDNA in various cancers. The potential, challenges, and future directions of genomic and epigenomic analysis of cfDNA in oncology are discussed. Cell-free DNA (cfDNA) analysis using liquid biopsies is a non-invasive method to gain insights into the biology, therapy response, mechanisms of acquired resistance and therapy escape of various tumors. While it is well established that individual cancer treatment options can be adjusted by panel next-generation sequencing (NGS)-based evaluation of driver mutations in cfDNA, emerging research additionally explores the value of deep characterization of tumor cfDNA genomics and fragmentomics as well as nucleosome modifications (chromatin structure), and methylation patterns (epigenomics) for comprehensive and multi-modal assessment of cfDNA. These tools have the potential to improve disease monitoring, increase the sensitivity of minimal residual disease identification, and detection of cancers at earlier stages. Recent progress in emerging technologies of cfDNA analysis is summarized, the added potential clinical value is highlighted, strengths and limitations are identified and compared with conventional targeted NGS analysis, and current challenges and future directions are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
- Author
-
Alcantara, Krizelle Mae M., Malapit, Joshua Reginald P., Yu, Ryan Timothy D., Garrido, Jose Antonio Ma. G., Rigor, John Paul T., Angeles, Arlou Kristina J., Cutiongco-de la Paz, Eva Maria, and Garcia, Reynaldo L.
- Subjects
RAS oncogenes ,COLORECTAL cancer ,EPIDERMAL growth factor receptors ,CELL transformation ,MOLECULAR switches - Abstract
RAS oncogene family members are molecular switches of signaling pathways that control cell growth, proliferation, differentiation, and survival. In colorectal cancer, Kirsten-RAS (KRAS) and neuroblastoma-RAS (NRAS) are the commonly mutated isoforms. Activating mutations in RAS result in cellular transformation independent of upregulated epidermal growth factor receptor (EGFR)-initiated signaling. The present study characterized the functional consequences of non-canonical/novel KRAS and NRAS mutants identified in a targeted next-generation sequencing study of colorectal cancer specimens from Filipino patients. In vitro assays in NIH3T3 cells showed that similar to the canonical KRAS G12D mutant, overexpression of KRAS G12S, A59T, and Y137C, but not NRAS G12D and NRAS A11V, confer higher proliferation and migration rates. HCT116 cells transfected with the novel NRAS A11V and the canonical NRAS G12D, but not the KRAS mutants, display enhanced resistance to apoptosis. All four non-canonical/novel KRAS and NRAS mutants induce gross changes in F-actin cytoskeletal organization and cellular morphology of NIH3T3 cells. Only KRAS G12S and KRAS A59T appear to deregulate extracellular signal-regulated kinase (ERK) and its downstream target ETS transcription factor ELK1 (ELK1). Elucidation of differential effector engagement responsible for the variable phenotypic readouts of the mutants is warranted. If validated by mouse studies and clinical correlates, these can have wider implications in choosing treatment options. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Genome-Based Classification and Therapy of Prostate Cancer.
- Author
-
Angeles, Arlou Kristina, Bauer, Simone, Ratz, Leonie, Klauck, Sabine M., and Sültmann, Holger
- Subjects
- *
PROSTATE cancer treatment , *PROSTATE cancer & genetics , *TRANSCRIPTOMES , *CARCINOGENESIS , *CLINICAL trials - Abstract
In the past decade, multi-national and multi-center efforts were launched to sequence prostate cancer genomes, transcriptomes, and epigenomes with the aim of discovering the molecular underpinnings of tumorigenesis, cancer progression, and therapy resistance. Multiple biological markers and pathways have been discovered to be tumor drivers, and a molecular classification of prostate cancer is emerging. Here, we highlight crucial findings of these genome-sequencing projects in localized and advanced disease. We recapitulate the utility and limitations of current clinical practices to diagnosis, prognosis, and therapy, and we provide examples of insights generated by the molecular profiling of tumors. Novel treatment concepts based on these molecular alterations are currently being addressed in clinical trials and will lead to an enhanced implementation of precision medicine strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors.
- Author
-
Schindler H, Lusky F, Daniello L, Elshiaty M, Gaissmaier L, Benesova K, Souto-Carneiro M, Angeles AK, Janke F, Eichhorn F, Kazdal D, Schneider M, Liersch S, Klemm S, Schnitzler P, Stenzinger A, Sültmann H, Thomas M, and Christopoulos P
- Abstract
Introduction: PD-(L)1 inhibitors (IO) have improved the prognosis of non-small-cell lung cancer (NSCLC), but more reliable predictors of efficacy and immune-related adverse events (irAE) are urgently needed. Cytokines are important effector molecules of the immune system, whose potential clinical utility as biomarkers remains unclear., Methods: Serum samples from patients with advanced NSCLC receiving IO either alone in the first (1L, n=46) and subsequent lines (n=50), or combined with chemotherapy (ICT, n=108) were analyzed along with age-matched healthy controls (n=15) at baseline, after 1 and 4 therapy cycles, and at disease progression (PD). Patients were stratified in rapid progressors (RP, progression-free survival [PFS] <120 days), and long-term responders (LR, PFS >200 days). Cytometric bead arrays were used for high-throughput quantification of 20 cytokines and other promising serum markers based on extensive search of the current literature., Results: Untreated NSCLC patients had increased levels of various cytokines and chemokines, like IL-6, IL-8, IL-10, CCL5, G-CSF, ICAM-1, TNF-RI and VEGF (fold change [FC]=1.4-261, p=0.026-9x10
-7 ) compared to age-matched controls, many of which fell under ICT (FC=0.2-0.6, p=0.014-0.002), but not under IO monotherapy. Lower baseline levels of TNF-RI were associated with longer PFS (hazard ratio [HR]= 0.42-0.54; p=0.014-0.009) and overall survival (HR=0.28-0.34, p=0.004-0.001) after both ICT and IO monotherapy. Development of irAE was associated with higher baseline levels of several cytokines, in particular of IL-1β and angiogenin (FC=7-9, p=0.009-0.0002). In contrast, changes under treatment were very subtle, there were no serum correlates of radiologic PD, and no association between dynamic changes in cytokine concentrations and clinical outcome. No relationship was noted between the patients' serologic CMV status and serum cytokine levels., Conclusions: Untreated NSCLC is characterized by increased blood levels of several pro-inflammatory and angiogenic effectors, which decrease under ICT. Baseline serum cytokine levels could be exploited for improved prediction of subsequent IO benefit (in particular TNF-RI) and development of irAE ( e.g. IL-1β or angiogenin), but they are not suitable for longitudinal disease monitoring. The potential utility of IL-1/IL-1β inhibitors in the management and/or prevention of irAE in NSCLC warrants investigation., Competing Interests: Author KB received consultancy and/or speaker fees and/or travel reimbursements from Abbvie, Bristol Myers Squibb BMS, Gilead/Galapagos, Janssen, Merck Sharp & Dohme MSD, Mundipharma, Novartis, Pfizer, Roche, Viatris, UCB, as well as scientific support from the Medical Faculty of University of Heidelberg, Rheumaliga Baden-Württemberg e.V., AbbVie, and Novartis. Author FE received personal fees from Roche and BMS; DK: advisory board and speaker’s honoraria from AstraZeneca, BMS, Pfizer. Author AS received advisory board honoraria from BMS, AstraZeneca, ThermoFisher, Novartis, speaker’s honoraria from BMS, Illumina, AstraZeneca, Novartis, ThermoFisher, MSD, Roche, and research funding from Chugai. Author HoS received research grants and personal fees from Roche Sequencing Solutions, outside the submitted work. Author MT received advisory board honoraria from Novartis, Lilly, BMS, MSD, Roche, Celgene, Takeda, AbbVie, Boehringer, speaker’s honoraria from Lilly, MSD, Takeda, research funding from AstraZeneca, BMS, Celgene, Novartis, Roche and travel grants from BMS, MSD, Novartis, Boehringer. Author PC received research funding from Amgen, AstraZeneca, Merck, Novartis, Roche, Takeda, and advisory board/lecture fees from AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Gilead, Novartis, Pfizer, Roche, Takeda. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Schindler, Lusky, Daniello, Elshiaty, Gaissmaier, Benesova, Souto-Carneiro, Angeles, Janke, Eichhorn, Kazdal, Schneider, Liersch, Klemm, Schnitzler, Stenzinger, Sültmann, Thomas and Christopoulos.)- Published
- 2022
- Full Text
- View/download PDF
10. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
- Author
-
Dietz S, Christopoulos P, Yuan Z, Angeles AK, Gu L, Volckmar AL, Ogrodnik SJ, Janke F, Fratte CD, Zemojtel T, Schneider MA, Kazdal D, Endris V, Meister M, Muley T, Cecchin E, Reck M, Schlesner M, Thomas M, Stenzinger A, and Sültmann H
- Subjects
- Aged, Biomarkers, Tumor, Female, High-Throughput Nucleotide Sequencing, Humans, Lung Neoplasms diagnosis, Lung Neoplasms drug therapy, Lung Neoplasms mortality, Male, Middle Aged, Molecular Targeted Therapy adverse effects, Molecular Targeted Therapy methods, Prognosis, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Treatment Outcome, Circulating Tumor DNA, DNA Copy Number Variations, Lung Neoplasms genetics, Mutation
- Abstract
Background: Targeted therapies (TKI) have improved the prognosis of ALK-rearranged lung cancer (ALK
+ NSCLC), but clinical courses vary widely. Early identification and molecular characterisation of treatment failure have key importance for subsequent therapies. We performed copy number variation (CNV) profiling and targeted panel sequencing from cell-free DNA (cfDNA) to monitor ALK+ NSCLC., Methods: 271 longitudinal plasma DNA samples from 73 patients with TKI-treated metastatic ALK+ NSCLC were analysed by capture-based targeted (average coverage 4,100x), and shallow whole genome sequencing (sWGS, 0.5x). Mutations were called using standard algorithms. CNVs were quantified using the trimmed median absolute deviation from copy number neutrality (t-MAD)., Findings: cfDNA mutations were identified in 58% of patients. They included several potentially actionable alterations, e.g. in the genes BRAF, ERBB2, and KIT. sWGS detected CNVs in 18% of samples, compared to 6% using targeted sequencing. Several of the CNVs included potentially druggable targets, such as regions harboring EGFR, ERBB2, and MET. Circulating tumour DNA (ctDNA) mutations and t-MAD scores increased during treatment, correlated with markers of higher molecular risk, such as the EML4-ALK variant 3 and/or TP53 mutations, and were associated with shorter patient survival. Importantly, t-MAD scores reflected the tumour remission status in serial samples similar to mutant ctDNA allele frequencies, and increased with disease progression in 79% (34/43) of cases, including those without detectable single nucleotide variant (SNV)., Interpretation: Combined copy number and targeted mutation profiling could improve monitoring of ALK+ NSCLC. Potential advantages include the identification of treatment failure, in particular for patients without detectable mutations, and broader detection of genomic changes acquired during therapy, especially in later treatment lines and in high-risk patients., Funding: This work was supported by the German Center for Lung Research (DZL), by the German Cancer Consortium (DKTK), by the Heidelberg Center for Personalized Oncology at the German Cancer Research Center (DKFZ-HIPO), and by Roche Sequencing Solutions (Pleasanton, CA, USA)., (Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
11. The ERG-Regulated LINC00920 Promotes Prostate Cancer Cell Survival via the 14-3-3ε-FOXO Pathway.
- Author
-
Angeles AK, Heckmann D, Flosdorf N, Duensing S, and Sültmann H
- Subjects
- 14-3-3 Proteins genetics, Cell Line, Tumor, Cell Survival physiology, Forkhead Box Protein O1 genetics, Humans, Male, PC-3 Cells, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology, Transcriptional Regulator ERG genetics, Transcriptional Regulator ERG metabolism, Up-Regulation, 14-3-3 Proteins metabolism, Forkhead Box Protein O1 metabolism, Prostatic Neoplasms metabolism
- Abstract
Numerous noncoding transcripts have been reported to correlate with cancer development and progression. Nevertheless, there remains a paucity of long noncoding RNAs (lncRNA) with well-elucidated functional roles. Here, we leverage the International Cancer Genome Consortium-Early Onset Prostate Cancer transcriptome and identify the previously uncharacterized lncRNA LINC00920 to be upregulated in prostate tumors. Phenotypic characterization of LINC00920 revealed its positive impact on cellular proliferation, colony formation, and migration. We demonstrate that LINC00920 transcription is directly activated by ERG, an oncogenic transcription factor overexpressed in 50% of prostate cancers. Chromatin isolation by RNA purification-mass spectrometry revealed the interaction of LINC00920 with the 14-3-3ε protein, leading to enhanced sequestration of tumor suppressive FOXO1. Altogether, our results provide a rationale on how ERG overexpression, partly by driving LINC00920 transcription, could confer survival advantage to prostate cancer cells and potentially prime PTEN-intact prostate cells for cellular transformation through FOXO inactivation. IMPLICATIONS: The study describes a novel lncRNA-mediated mechanism of regulating the FOXO signaling pathway and provides additional insight into the role of ERG in prostate cancer cells., (©2020 American Association for Cancer Research.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.